|Table of Contents|

Flavokavin B promotes EGFR degradation and inhibits H1975 lung cancer cell proliferation and migration

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 01
Page:
17-24
Research Field:
Publishing date:

Info

Title:
Flavokavin B promotes EGFR degradation and inhibits H1975 lung cancer cell proliferation and migration
Author(s):
TANG Ying; LI Jinling; WANG Kejiang; YANG Zhongyun; LI Xuesen
Institute for Cancer Medicine,School of Basic Medical Sciences,Southwest Medical University,Sichuan Luzhou 646000,China.
Keywords:
lung cancer; Flavokavin B; EGFR-AKT signaling pathway
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2023.01.003
Abstract:
Objective:To study the effect of Flavokavin B on the proliferation and migration of lung cancer cell H1975 and explore its mechanism.Methods：H1975 lung cancer cell line was cultured and treated with different concentrations of Flavokavin B for 24,48 and 72 h.The effect of Flavokavin B on the proliferation of H1975 cell line was detected by CCK-8 method.Transwell assay was used to detect the effect of Flavokavin B on migration of H1975 cells.Western blotting was used to detect the expression of EGFR-AKT signaling pathway related proteins in H1975 cells treated with 20 μmol/L and 40 μmol/L Flavokavin B for 16 h.qPCR was used to detect the effect of Flavokavin B on EGFR mRNA level in H1975 cells.Western blotting was used to detect the expression of LC3-Ⅰ/Ⅱ protein in H1975 cells.CCK-8 assay and Transwell assay were used to determine the effects of the combination of Flavokavin B and EGFR small molecule inhibitor on the proliferation and migration of H1975 cells.Results:The proliferation of H1975 cells was inhibited in vitro in a concentration-dependent manner.The number of cell migration in treatment group was significantly decreased (P＜0.05).Western blotting results showed that the expression levels of EGFR,p-AKT and AKT protein in H1975 lung cancer cells were significantly decreased after treatment for 16 h (P＜0.05),but the mRNA level of EGFR in H1975 was not significantly changed.Flavokavin B-induced inhibition of EGFR protein was reversed when autophagy was blocked by Bafilomycin A1 (BAF) or Chloroquine (CQ).Moreover,Flavokavin B could promote the expression of LC3-Ⅱ protein in H1975 cells.The combination of Flavokavin B with EGFR small molecule inhibitor can inhibit the proliferation and migration of H1975 cells and the expression of p-EGFR and p-AKT.Conclusion：Flavokavin B can promote EGFR degradation and inhibit the proliferation and migration of H1975 lung cancer cells.

References:

［1］SIEGEL RL,MILLER KD,FUCHS HE,et al.Cancer statistics,2021［J］.CA Cancer J Clin,2021,71(1):7-33.
［2］SIEGEL R,WARD E,BRAWLEY O,et al.Cancer statistics,2011:the impact of eliminating socioeconomic and racial disparities on premature cancer deaths［J］.CA Cancer J Clin,2011,61(4):212-236.
［3］SIEGEL R,NAISHADHAM D,JEMAL A.Cancer statistics,2012［J］.CA Cancer J Clin,2012,62(1):10-29.
［4］YUAN C,JIANG H,JIANG W,et al.Comparison of different EGFR gene mutation status in patients with metastatic non-small lung cancer after first-line EGFR-TKIs therapy and analyzing its relationship with efficacy and prognosis［J］.Cancer Manag Res,2021,13:6901-6910.
［5］YANG CJ,HWANG JJ,KANG WY,et al.Gastro-intestinal metastasis of primary lung carcinoma:clinical presentations and outcome［J］.Lung Cancer,2006,54(3):319-323.
［6］HERBST RS,SHIN DM.Monoclonal antibodies to target epidermal growth factor receptor-positive tumors:a new paradigm for cancer therapy［J］.Cancer,2002,94(5):1593-1611.
［7］SCHLESSINGER J.Cell signaling by receptor tyrosine kinases［J］.Cell,2000,103(2):211-225.
［8］SCHLESSINGER J.Receptor tyrosine kinases:legacy of the first two decades［J］.Cold Spring Harb Perspect Biol,2014,6(3):1-13.
［9］SIGISMUND S,AVANZATO D,LANZETTI L.Emerging functions of the EGFR in cancer［J］.Mol Oncol,2018,12(1):3-20.
［10］CIARDIELLO F,TORTORA G.EGFR antagonists in cancer treatment［J］.N Engl J Med,2008,358(11):1160-1174.
［11］LI F,ZHAO X,SUN R,et al.EGFR-rich extracellular vesicles derived from highly metastatic nasopharyngeal carcinoma cells accelerate tumour metastasis through PI3K/AKT pathway-suppressed ROS［J］.J Extracell Vesicles,2020,10(1):e12003.
［12］LIU X,TIAN S,LIU M,et al.Wogonin inhibits the proliferation and invasion,and induces the apoptosis of HepG2 and Bel7402 HCC cells through NF-kappaB/Bcl-2,EGFR and EGFR downstream ERK/AKT signaling［J］.Int J Mol Med,2016,38(4):1250-1256.
［13］HSU FT,CHEN WT,WU CT,et al.Hyperforin induces apoptosis through extrinsic/intrinsic pathways and inhibits EGFR/ERK/NF-kappaB-mediated anti-apoptotic potential in glioblastoma［J］.Environ Toxicol,2020,35(10):1058-1069.
［14］ZHANG S,ZHU L,XIA B,et al.Epidermal growth factor receptor (EGFR) T790M mutation identified in plasma indicates failure sites and predicts clinical prognosis in non-small cell lung cancer progression during first-generation tyrosine kinase inhibitor therapy:a prospective observational study［J］.Cancer Commun (Lond),2018,38(1):1-14.
［15］KU BM,BAE YH,KOH J,et al.AZD9291 overcomes T790M-mediated resistance through degradation of EGFR(L858R/T790M) in non-small cell lung cancer cells［J］.Invest New Drugs,2016,34(4):407-415.
［16］LI X,PHAM V,TIPPIN M,et al.Flavokawain B targets protein neddylation for enhancing the anti-prostate cancer effect of Bortezomib via Skp2 degradation［J］.Cell Commun Signal,2019,17(1):1-13.
［17］JI T,LIN C,KRILL LS,et al.Flavokawain B,a kava chalcone,inhibits growth of human osteosarcoma cells through G2/M cell cycle arrest and apoptosis［J］.Mol Cancer,2013,12:1-11.
［18］ABU N,AKHTAR MN,YEAP SK,et al.Flavokawain B induced cytotoxicity in two breast cancer cell lines,MCF-7 and MDA-MB231 and inhibited the metastatic potential of MDA-MB231 via the regulation of several tyrosine kinases In vitro［J］.BMC Complement Altern Med,2016,16:1-14.
［19］TANG Y,LI X,LIU Z,et al.Flavokawain B,a kava chalcone,induces apoptosis via up-regulation of death-receptor 5 and Bim expression in androgen receptor negative,hormonal refractory prostate cancer cell lines and reduces tumor growth［J］.Int J Cancer,2010,127(8):1758-1768.
［20］CHANG CT,HSEU YC,THIYAGARAJAN V,et al.Chalcone flavokawain B induces autophagic-cell death via reactive oxygen species-mediated signaling pathways in human gastric carcinoma and suppresses tumor growth in nude mice［J］.Arch Toxicol,2017,91(10):3341-3364.
［21］LI X,LIU Z,XU X,et al.Kava components down-regulate expression of AR and AR splice variants and reduce growth in patient-derived prostate cancer xenografts in mice［J］.PLoS One,2012,7(2):e31213.
［22］LEE HJ,SHIN S,KANG J,et al.HSP90 inhibitor,17-DMAG,alone and in combination with lapatinib attenuates acquired lapatinib-resistance in ER-positive,HER2-overexpressing breast cancer cell line［J］.Cancers (Basel),2020,12(9):1-16.
［23］SONG JY,KIM CS,LEE JH,et al.Dual inhibition of MEK1/2 and EGFR synergistically induces caspase-3-dependent apoptosis in EGFR inhibitor-resistant lung cancer cells via BIM upregulation［J］.Invest New Drugs,2013,31(6):1458-1465.
［24］TAKAHASHI T,SAKAI K,KENMOTSU H,et al.Predictive value of EGFR mutation in non-small-cell lung cancer patients treated with platinum doublet postoperative chemotherapy［J］.Cancer Sci,2022,113(1):287-296.
［25］KHADDOUR K,JONNA S,DENEKA A,et al.Targeting the epidermal growth factor receptor in EGFR-mutated lung cancer:Current and emerging therapies［J］.Cancers (Basel),2021,13(13):1-24.
［26］CATALDO VD,GIBBONS DL,PEREZ-SOLER R,et al.Treatment of non-small-cell lung cancer with erlotinib or gefitinib［J］.N Engl J Med,2011,364(10):947-955.
［27］SANDERS DR,DONEY K,POCO M,et al.United States Food and Drug Administration clinical trial of the Implantable Collamer Lens (ICL) for moderate to high myopia:three-year follow-up［J］.Ophthalmology,2004,111(9):1683-1692.
［28］COHEN MH,JOHNSON JR,CHEN YF,et al.FDA drug approval summary:erlotinib (Tarceva) tablets［J］.Oncologist,2005,10(7):461-466.
［29］PAO W,MILLER VA,POLITI KA,et al.Acquired resistance of lung adenocarcinomas to Gefitinib or Erlotinib is associated with a second mutation in the EGFR kinase domain［J］.PLoS Med,2005,2(3):e73.
［30］YUN CH,MENGWASSER KE,TOMS AV,et al.The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP［J］.Proc Natl Acad Sci USA,2008,105(6):2070-2075.
［31］ZHANG L,LUO Y,CHEN J,et al.Efficacy and safety of Afatinib in the treatment of advanced non-small-cell lung cancer with EGFR mutations:A Meta-analysis of real-world evidence［J］.J Oncol,2021,2021:1-16.
［32］CROSS DA,ASHTON SE,GHIORGHIU S,et al.AZD9291,an irreversible EGFR TKI,overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer［J］.Cancer Discov,2014,4(9):1046-1061.
［33］JIANG P,MIZUSHIMA N.LC3- and p62-based biochemical methods for the analysis of autophagy progression in mammalian cells［J］.Methods,2015,75:13-18.
［34］GOLDBERG SB,REDMAN MW,LILENBAUM R,et al.Randomized trial of Afatinib plus Cetuximab versus Afatinib alone for first-line treatment of EGFR-mutant non-small-cell lung cancer:Final results from SWOG S1403［J］.J Clin Oncol,2020,38(34):4076-4085.

Memo

Memo:
National Natural Science Foundation of China（No.81603154）;国家自然科学青年科学基金项目（编号：81603154）
Last Update: 2022-11-30